Appendix 4E and 2025 Annual Report
Filed with ASX · · 53 pages · English
Summary by 6ix AI
The report indicates a loss for the consolidated entity after tax, alongside a significant increase in research and development tax incentive rebates for eligible expenses. No dividends were declared during the current or previous financial year, reflecting the company's focus on development activities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- Prescient successfully completes $3 million Placement
- June 2025 Quarterly Update and Appendix 4C
- Prescient announces results of SPP & Launches Placement
- Trading Halt
- Prescient Therapeutics - Extension of Share Purchase Plan
Later from Prescient Therapeutics
- September Quarterly Updated and Appendix 4C
- PTX secures EU Orphan Drug Designation for PTX-100 in CTCL
- PTX secures EU Authorisation to commence PTX-100 Trial
- December 2025 Quarterly Update and Appendix 4C
- Appendix 4D and Half Year Financial Report
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics